Triterpenoids and Derivatives with Anticancer Activity
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (30 July 2021) | Viewed by 8097
Special Issue Editor
Interests: semisynthetic steroids; diterpenoid and triterpenoid derivatives with improved antitumor activity and investigation of their mechanisms of anticancer action; cancer research; novel PARP-1 inhibitors; enzyme inhibitors able to tackle hormone-dependent cancers, such as 5alpha-reductase and CYP17 inhibitors; new drugs acting on the ubiquitin–proteasome system (UPS); inhibitors of BACE1 and glutaminyl cyclase for Alzheimer’s disease treatment; green pharmaceutical processes
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Natural products and their derivatives are a rich source of successful drug leads. A historical assessment of all FDA-approved new molecular entities (NMEs) reveals that natural products and their analogues represent over one-third of all NMEs. Triterpenes, also called triterpenoids when functionalized, are structurally diverse natural products that originate from squalene or oxidosqualene through a series of intramolecular condensation reactions. In recent years, there has been enormous interest in terpenoid natural products and their semisynthetic derivatives due to their remarkable structural diversity and wide range of pharmacological activities.
In nature, triterpenoids are often found as tetra- or pentacyclic structures, but acyclic, mono-, bi-, tri- and hexacyclic triterpenes also exist. Tetracyclic triterpenoids, including the dammarane, cucurbitane, cycloartane, lanostane, and protostane groups, comprise triterpenoids that are widely distributed in various medicinal plants, some of them with potent anticancer activity. Pentacyclic triterpenoids can be divided into several representative classes, namely, ursanes, oleananes, and lupanes, which all include interesting bioactive compounds with immunomodulatory, anti-inflammatory, and anticancer activities. This Special Issue aims to provide the opportunity to share new findings and recent advances on triterpenoids and their derivatives toward the development of new anticancer drugs.
Prof. Dr. Jorge A. R. Salvador
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Natural triterpenoids
- Tetracyclic triterpenoids and derivatives
- Pentacyclic triterpenoids and derivatives
- Others semisynthethic triterpenoids and derivatives
- Anticancer activity
